P
Patrick A. Mayes
Researcher at GlaxoSmithKline
Publications - 23
Citations - 1202
Patrick A. Mayes is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Antibody & Antigen. The author has an hindex of 8, co-authored 23 publications receiving 856 citations.
Papers
More filters
Journal ArticleDOI
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.
Yu-Tzu Tai,Patrick A. Mayes,Chirag Acharya,Mike Y Zhong,Michele Cea,Antonia Cagnetta,Jenny L Craigen,John Yates,Louise Gliddon,William E. Fieles,Bao Hoang,James Tunstead,Amanda L. Christie,Andrew L. Kung,Paul G. Richardson,Nikhil C. Munshi,Kenneth C. Anderson +16 more
TL;DR: It is demonstrated that GSK2857916 has potent and selective anti-MM activities via multiple cytotoxic mechanisms, providing a promising next-generation immunotherapeutic in this cancer.
Journal ArticleDOI
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
Li Liu,Patrick A. Mayes,Stephen Eastman,Hong Shi,Sapna Yadavilli,Tianqian Zhang,Jingsong Yang,Laura M. Seestaller-Wehr,Shu-Yun Zhang,Chris Hopson,Lyuben Tsvetkov,Junping Jing,Shu Zhang,James F. Smothers,Axel Hoos +14 more
TL;DR: Findings support the potential for synergy between targeted therapies dabrafenib and trametinib and immunomodulatory antibodies in vivo and clinical exploration of such combination regimens is under way.
Journal ArticleDOI
The promise and challenges of immune agonist antibody development in cancer.
TL;DR: This Review discusses the key considerations and potential pitfalls of immune agonist antibody design and development, their differentiating features from antagonist antibodies and the landscape of agonist antibodies in clinical development for cancer treatment.
Journal ArticleDOI
Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma
Lydia Lee,Danton Bounds,Jennifer C. Paterson,Gaelle Herledan,Katherine Sully,Laura M. Seestaller-Wehr,William E. Fieles,James Tunstead,Lee Mccahon,Fiona Germaschewski,Patrick A. Mayes,Jenny L Craigen,Manuel Rodriguez-Justo,Kwee Yong +13 more
TL;DR: Observed rapid internalization of surface BCMA and newly expressed protein by 1 h, suggesting a mechanism for J6M0‐MMAF activity even with low surface antigen, and support BCMA to be a promising therapeutic target in MM for novel therapies such as J6m0‐ MMAF.
Journal ArticleDOI
Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-Mediated Anti-Tumor Responses In Vivo
Rocio Montes de Oca,Alireza S Alavi,Nick Vitali,Sabyasachi Bhattacharya,Christina Blackwell,Krupa Patel,Laura M. Seestaller-Wehr,Heather Kaczynski,Hong Shi,Dobrzynski Eric,Leslie A. Obert,Lyuben Tsvetkov,David C Cooper,Heather Jackson,Paul Bojczuk,Sabrina Forveille,Oliver Kepp,Allan Sauvat,Guido Kroemer,Mark Creighton-Gutteridge,Jingsong Yang,Chris Hopson,Niranjan Yanamandra,Christopher A. Shelton,Patrick A. Mayes,Joanna Opalinska,Mary S. Barnette,Roopa Srinivasan,James F. Smothers,Axel Hoos +29 more
TL;DR: GSK2857916 (belantamab mafodotin, BLENREP) is a BCMA-targeting antibody-drug-conjugate for the treatment of relapsed/refractory multiple myeloma (MM) and other B-cell malignancies as mentioned in this paper.